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BACKGROUND
It is controversial whether maternal hyperglycemia less severe than that in diabetes 
mellitus is associated with increased risks of adverse pregnancy outcomes.
METHODS
A total of 25,505 pregnant women at 15 centers in nine countries underwent 75-g 
oral glucose-tolerance testing at 24 to 32 weeks of gestation. Data remained blinded 
if the fasting plasma glucose level was 105 mg per deciliter (5.8 mmol per liter) or 
less and the 2-hour plasma glucose level was 200 mg per deciliter (11.1 mmol per 
liter) or less. Primary outcomes were birth weight above the 90th percentile for ges-
tational age, primary cesarean delivery, clinically diagnosed neonatal hypoglyce-
mia, and cord-blood serum C-peptide level above the 90th percentile. Secondary 
outcomes were delivery before 37 weeks of gestation, shoulder dystocia or birth 
injury, need for intensive neonatal care, hyperbilirubinemia, and preeclampsia.
RESULTS
For the 23,316 participants with blinded data, we calculated adjusted odds ratios for 
adverse pregnancy outcomes associated with an increase in the fasting plasma glu-
cose level of 1 SD (6.9 mg per deciliter [0.4 mmol per liter]), an increase in the 1-hour 
plasma glucose level of 1 SD (30.9 mg per deciliter [1.7 mmol per liter]), and an in-
crease in the 2-hour plasma glucose level of 1 SD (23.5 mg per deciliter [1.3 mmol 
per liter]). For birth weight above the 90th percentile, the odds ratios were 1.38 
(95% confidence interval [CI], 1.32 to 1.44), 1.46 (1.39 to 1.53), and 1.38 (1.32 to 1.44), 
respectively; for cord-blood serum C-peptide level above the 90th percentile, 1.55 
(95% CI, 1.47 to 1.64), 1.46 (1.38 to 1.54), and 1.37 (1.30 to 1.44); for primary cesar-
ean delivery, 1.11 (95% CI, 1.06 to 1.15), 1.10 (1.06 to 1.15), and 1.08 (1.03 to 1.12); 
and for neonatal hypoglycemia, 1.08 (95% CI, 0.98 to 1.19), 1.13 (1.03 to 1.26), and 
1.10 (1.00 to 1.12). There were no obvious thresholds at which risks increased. Sig-
nificant associations were also observed for secondary outcomes, although these 
tended to be weaker.
CONCLUSIONS
Our results indicate strong, continuous associations of maternal glucose levels below 
those diagnostic of diabetes with increased birth weight and increased cord-blood se-
rum C-peptide levels.
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Gestational diabetes mellitus, de-fined as “glucose intolerance with onset or first recognition during pregnancy,”1,2 
has been the subject of considerable controversy. 
Criteria for the diagnosis were initially established 
more than 40 years ago3 and, with minor modi-
fications, remain in use today. These criteria are 
not designed to identify pregnant women who are 
at increased risk for adverse perinatal outcomes 
but rather women who are at high risk for the de-
velopment of diabetes after pregnancy,3,4 or they 
are the criteria used for the general population.5
Overt diabetes mellitus during pregnancy is 
associated with significantly increased risks of 
adverse perinatal outcomes. Whereas some data 
suggest that current diagnostic criteria for ges-
tational diabetes mellitus1 are too restrictive and 
that lesser degrees of hyperglycemia also increase 
risk,6-11 risks associated with hyperglycemia that 
is less severe than that diagnostic of overt diabetes 
mellitus are uncertain for a number of reasons. 
First, there are no uniform international standards 
for the ascertainment and diagnosis of gesta-
tional diabetes mellitus.2 In addition, the extent 
to which adverse outcomes associated with gesta-
tional diabetes mellitus may be explained by con-
founders (including obesity, advanced maternal 
age, or associated medical complications) is un-
clear.12-14 Caregiver bias (i.e., an expectation of 
adverse outcomes due to gestational diabetes mel-
litus) may increase the likelihood of disorders or 
problems due to increased intervention.15
We conducted the Hyperglycemia and Adverse 
Pregnancy Outcome (HAPO) study to clarify the 
risks of adverse outcomes associated with various 
degrees of maternal glucose intolerance less se-
vere than that in overt diabetes mellitus.
Me thods
The protocol was approved by the institutional re-
view board at each field center. All participants 
gave written informed consent. An external data 
and safety monitoring committee provided over-
sight. The study methods have been published pre-
viously.16,17 A brief overview is presented here.
Participants
All pregnant women at a given center were eligi-
ble to participate unless they had one or more of 
the following exclusion criteria16: age younger than 
18 years, a plan to undergo delivery at another hos-
pital, an uncertain date of last menstrual period 
and no ultrasonographic estimation between 6 and 
24 weeks of gestational age, inability to complete 
the oral glucose-tolerance test within 32 weeks 
of gestation, multiple pregnancy, conception by 
means of gonadotropin ovulation induction or in 
vitro fertilization, glucose testing before recruit-
ment or a diagnosis of diabetes during the cur-
rent pregnancy, diagnosis of diabetes before the 
current pregnancy and requiring treatment with 
medication, participation in another study that 
could interfere with the HAPO study, infection 
with the human immunodeficiency virus or hep-
atitis B or C virus, previous participation in the 
HAPO study, or inability to converse in the lan-
guages used on center forms without the aid of an 
interpreter. If glucose measurements were made 
outside the setting of the HAPO study after ini-
tial enrollment, participation was terminated. Age 
and education level were recorded for women who 
declined to participate.
Gestational age and expected date of delivery 
were determined from the date of the last men-
strual period, if the date was certain. If the date 
was uncertain, the expected date of delivery was 
estimated by means of ultrasonography performed 
between 6 and 24 weeks of gestation. The final 
expected date of delivery was also determined with 
the use of ultrasonography if the gestational age 
estimated on the basis of the date of the last men-
strual period differed by more than 5 days from 
that based on ultrasonography performed between 
6 and 13 weeks of gestation or by more than 10 
days from that based on ultrasonography per-
formed between 14 and 24 weeks of gestation.
Oral Glucose-Tolerance Test
Participants underwent a standard oral glucose-
tolerance test, with the use of a 75-g dose of glu-
cose, between 24 and 32 weeks of gestation (tar-
get time of testing, 28 weeks). Height, weight, and 
blood pressure were measured at the test visit. Data 
concerning smoking and alcohol use, history of 
diabetes and hypertension among first-degree fam-
ily members, and demographic characteristics were 
collected by means of standardized questionnaires. 
Race or ethnic group was self-reported by partici-
pants. A blood specimen was collected between 
34 and 37 weeks of gestation for evaluation of the 
random plasma glucose level, as a safety measure 
to identify cases with hyperglycemia above a pre-
defined threshold.
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on March 30, 2017. For personal use only. No other uses without permission. 
 Copyright © 2008 Massachusetts Medical Society. All rights reserved. 
Hyperglycemia and Adverse Pregnancy Outcomes
n engl j med 358;19 www.nejm.org may 8, 2008 1993
Glucose Analysis
For purposes of clinical decision making, plasma 
glucose levels were measured at center laborato-
ries by means of enzymatic methods, with exten-
sive quality control, as previously described.17 To 
avoid the confounding effects of analytic variation 
among centers, aliquots of all oral glucose-toler-
ance test specimens were analyzed at the central 
laboratory of the HAPO study, and the results were 
used in the analyses reported here.
Unblinding of Data
Fasting and 2-hour specimens from the oral glu-
cose-tolerance tests and the blood specimen taken 
for determination of the random plasma glucose 
level were analyzed at center laboratories. The data 
were unblinded if the 2-hour plasma glucose lev-
el was diagnostic of diabetes (i.e., >200 mg per 
deciliter [11.1 mmol per liter]) or, for ethical and 
safety reasons, if the fasting plasma glucose level 
exceeded 105 mg per deciliter (5.8 mmol per liter), 
the random plasma glucose level was 160 mg per 
deciliter (8.9 mmol per liter) or more, or any plas-
ma glucose level was less than 45 mg per deciliter 
(2.5 mmol per liter). Otherwise, women, caregiv-
ers, and the staff of the HAPO study (except for 
laboratory personnel) remained unaware of the 
glucose values. Only women whose data were 
blinded and who did not undergo any additional 
glucose testing outside the HAPO study were in-
cluded in our analyses.
Cord-Blood Plasma Glucose and Serum  
C-Peptide Levels
Cord-blood specimens were collected at delivery 
for the measurement of serum C-peptide and plas-
ma glucose levels. The specimens were analyzed 
at the central laboratory with the use of an im-
munoassay (AutoDELFIA, PerkinElmer) for serum 
C peptide and a chemical analyzer (Vitros 750, 
Ortho-Clinical Diagnostics) for plasma glucose.17 
Because approximately 15% of cord-blood samples 
have detectable hemolysis after serum or plasma 
is separated out, because hemolysis is known to 
increase insulin degradation but not to affect 
C-peptide level,17 and because C peptide and in-
sulin are secreted in equimolar levels, we used 
cord-blood serum C-peptide level rather than in-
sulin level as our index of fetal β-cell function.
Prenatal Care, Delivery, and Neonatal Care
Prenatal care, timing of delivery, and neonatal care 
were determined by means of the standard prac-
tice at each center. No center arbitrarily induced 
delivery before full term or routinely performed 
cesarean delivery at a specified maternal or ges-
tational age. Medical records were abstracted to 
obtain data regarding the prenatal course, labor 
and delivery, the postpartum course, and the new-
born course.
Outcomes
Primary and Secondary Outcomes
The four primary outcomes were birth weight 
above the 90th percentile for gestational age, pri-
mary cesarean delivery, clinical neonatal hypogly-
cemia, and cord-blood serum C-peptide level above 
the 90th percentile (fetal hyperinsulinemia). Sec-
ondary outcomes were premature delivery (before 
37 weeks of gestation), shoulder dystocia or birth 
injury, need for intensive neonatal care, hyperbili-
rubinemia, and preeclampsia.
Possible Severe Adverse Outcomes
Additional data were abstracted at centers when-
ever a possible severe adverse event (e.g., death, 
shoulder dystocia, birth injury, and major malfor-
mation) was identified. Data were reviewed by the 
members of an outcome review committee, who 
were unaware of the mother’s glycemic status, to 
confirm whether the event was present. Perinatal 
deaths were classified according to the Australian 
and New Zealand Antecedent Classification of 
Perinatal Mortality guidelines,18 and major mal-
formations were classified according to codes of 
the International Classification of Diseases, Tenth Revi-
sion.19 The HAPO data and safety monitoring com-
mittee reviewed data regarding adverse outcomes 
and deaths after having been made aware of the 
results of the oral glucose-tolerance test and the 
random plasma glucose levels.
Statistical Analysis
Mean and standard deviation are reported for con-
tinuous variables, and number and percentage are 
reported for categorical variables. Pearson product-
moment correlations were used to assess associ-
ations among glucose measures. For associations 
of glycemia with primary outcomes, as prespec-
ified in the HAPO study protocol, each glucose 
measurement was considered as both a categori-
cal and a continuous variable in multiple logistic-
regression analyses. For secondary outcomes, only 
results for continuous variables are presented. For 
categorical analyses, each measure of glycemia 
was divided into seven categories, such that the 
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1- and 2-hour plasma glucose measures reflected 
data for approximately the same number of wom-
en in each category as did the fasting plasma 
glucose measure. Categories for the fasting plas-
ma glucose level were originally prespecified in 
the HAPO study protocol as 100 mg per deciliter 
(5.6 mmol per liter) or more, 95 to 99 (5.3 to 5.5), 
90 to 94 (5.0 to 5.2), 85 to 89 (4.8 to 4.9), and less 
than 85. Subsequently, the category of less than 
85 mg per deciliter was further subdivided into 
less than 75 mg per deciliter (4.2 mmol per liter), 
75 to 79 (4.2 to 4.4), and 80 to 84 (4.5 to 4.7). The 
highest and second-highest categories for each 
glucose measure, accounting for 1% and 3% of 
participants, respectively, were specifically chosen 
to allow for assessment of whether there were 
threshold effects.
For continuous-variable analyses, odds ratios 
were calculated for a 1-SD increase in fasting, 
1-hour, and 2-hour plasma glucose levels. As pre-
specified, to assess whether the log of the odds of 
each outcome was linearly related to glucose level, 
we added squared terms for glucose level for each 
adverse pregnancy outcome to assess whether 
there were significant quadratic associations. For 
each outcome, two logistic models were fit.
Table 1. Characteristics of the Study Participants and Their Newborns and Frequency of Outcomes.*
Characteristic or Outcome
No. of Participants 
(%) Mean ±SD
Range of Means 
among Centers
Maternal characteristics
Age (yr) 23,316 (100) 29.2±5.8 25.4–33.6
Body-mass index 23,316 (100) 27.7±5.1 24.4–29.9
Mean arterial pressure (mm Hg) 23,316 (100) 80.9±8.3 75.9–84.1
Plasma glucose (mg/dl)
Fasting 23,316 (100) 80.9±6.9 78.2–83.7
1 hr 23,316 (100) 134.1±30.9 119.5–148.2
2 hr 23,316 (100) 111.0±23.5 99.6–120.9
Length of gestation at time of OGTT (wk) 23,316 (100) 27.8±1.8 25.9–29.5
Any prenatal smoking — % 1,581 (6.8) 0.2–23.7
Any prenatal alcohol use — % 1,612 (6.9) 0.1–26.5
Family history of diabetes — % 5,282 (22.7) 12.1–37.7
Parity (delivery ≥20 wk) at enrollment 12,233 (52.5) 34.8–68.9
Prenatal urinary tract infection — % 1,655 (7.1) 0.4–22.5
Hospitalization before delivery — % 3,271 (14.0) 2.3–33.2
Newborn characteristics
Gestational age at delivery (wk) 23,316 (100) 39.4±1.7 38.7–39.9
Birth weight (g) 23,217 (99.6) 3292±529 3109–3526
Cord-blood serum C peptide (μg/liter) 19,885 (85.3) 1.0±0.6 0.9–1.2
Cord-blood plasma glucose (mg/dl) 19,859 (85.2) 81.5±19.6 74.2–90.4
Male sex — % 12,003 (51.5) 49.3–54.0
Obstetrical outcomes
Cesarean delivery — %
Primary 3,731 (16.0) 8.6–23.5
Repeat 1,792 (7.7) 3.3–11.8
Hypertension — %†
Chronic hypertension 582 (2.5) 0.5–9.4
Gestational hypertension 1,370 (5.9) 0.7–17.7
Preeclampsia 1,116 (4.8) 1.4–11.4
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Model I included adjustment for center or the 
variables used in estimating the 90th percentile 
for birth weight for gestational age (infant’s sex, 
race or ethnic group, center, and parity). Model II 
included adjustment for multiple potential pre-
specified confounders, including age, body-mass 
index (BMI), smoking status, alcohol use, pres-
ence or absence of a family history of diabetes, 
gestational age at the oral glucose-tolerance test, 
sex of the infant, parity (0, 1, or ≥2, except for 
primary cesarean deliveries), mean arterial pres-
sure and presence or absence of hospitalization 
before delivery (except for preeclampsia), and pres-
ence or absence of a family history of hyperten-
sion and maternal urinary tract infection (for 
analysis of preeclampsia only). Height was also 
included as a potential confounder, on the basis 
of post hoc findings of an association with birth 
weight greater than the 90th percentile, and two 
prespecified confounders (maternal urinary tract 
infection and previous prenatal death) were exclud-
ed from primary and secondary outcome analy-
ses when neither was found to be related to any 
primary outcome or to affect primary outcome–
glucose associations. Squared terms for age, BMI, 
and mean arterial pressure were prescreened for 
possible inclusion in model II adjustment when 
only the center had been included (i.e., models 
without glucose or other covariates); these terms 
were included in model II when significant. Only 
Table 1. (Continued.)
Characteristic or Outcome
No. of Participants 
(%) Mean ±SD
Range of Means 
among Centers
Newborn outcomes
Birth weight >90th percentile — %‡ 2,221 (9.5) 9.0–9.9
Clinical neonatal hypoglycemia — %§ 480 (2.1) 0.3–6.4
Cord-blood serum C peptide >90th percentile — %¶ 1,671 (8.4) 5.9–15.1
Premature delivery (before 37 wk) — % 1,608 (6.9) 3.9–9.1
Shoulder dystocia or birth injury 311 (1.3) 0.1–3.4
Intensive neonatal care — %‖ 1,855 (8.0) 3.0–28.8
Hyperbilirubinemia — %** 1,930 (8.3) 3.0–25.4
*  The body-mass index (the weight in kilograms divided by the square of the height in meters), mean arterial pressure, 
and glucose levels were obtained at the oral glucose-tolerance test (OGTT). To convert the values for glucose to milli-
moles per liter, multiply by 0.05551. For additional characteristics of the participants, see Table A in the Supplemen-
tary Appendix.
†  Chronic hypertension was defined as hypertension that was present before 20 weeks of gestation and that did not 
progress to preeclampsia. Hypertension disorders occurring during pregnancy after 20 weeks of gestation were cate-
gorized according to the International Society for the Study of Hypertension guidelines.20 Preeclampsia was defined 
as systolic blood pressure of 140 mm Hg or more or diastolic blood pressure of 90 mm Hg or more on two or more 
occasions a minimum of 6 hours apart and proteinuria of 1+ or more on a dipstick test or a protein level in the urine 
of 300 mg or more for a 24-hour period. If the criteria for elevated blood pressure were met but those for proteinuria 
were not, the hypertension was classified as gestational hypertension.
‡  For birth weight above the 90th percentile, the 90th percentiles for gestational age (30 to 44 weeks only) were deter-
mined with the use of quantile regression analyses for each of eight groups of newborns based on infant’s sex and 
race or ethnic group (white or other, black, Hispanic, or Asian), with adjustment for gestational age, field center, and 
parity (0, 1, or ≥2). A newborn was considered to have a birth weight above the 90th percentile if the birth weight was 
greater than the estimated 90th percentile for the infant’s sex, gestational age, race or ethnic group, field center, and 
maternal parity. Otherwise, the newborn was considered to have a birth weight at or under the 90th percentile. Birth 
weights were available for 23,217 newborns.
§  Clinical neonatal hypoglycemia was defined as being present if there was a notation of neonatal hypoglycemia in the 
medical record and there were symptoms or treatment with a glucose infusion or a local laboratory report of a glu-
cose value of 30.6 mg per deciliter (1.7 mmol per liter) or less in the first 24 hours after birth or 45.0 mg per deciliter 
(2.5 mmol per liter) or less after the first 24 hours.21
¶  A cord-blood serum C-peptide level above the 90th percentile was defined on the basis of the 19,885 newborns for 
whom data were available.
‖  Intensive neonatal care was defined by admission to any type of unit for care more intensive than normal newborn 
care and lasting more than 24 hours or by death of the baby or transfer to another hospital. Data were excluded for 
admissions that were only for possible sepsis or sepsis, observation, or feeding problems.
** Hyperbilirubinemia was defined by treatment with phototherapy after birth, at least one laboratory report of a biliru-
bin level of 20 mg per deciliter (342 μmol per liter) or more, or readmission for hyperbilirubinemia.
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the fully adjusted model results are presented in 
this report. (Results for all models are given in 
Tables B through F in the Supplementary Ap-
pendix, available with the full text of this article 
at www.nejm.org.)
In post hoc analyses, we tested for interactions 
of each glucose measure with center in models I 
and II (except with regard to the outcomes of 
clinical neonatal hypoglycemia and shoulder dys-
tocia or birth injury, owing to small numbers in 
some centers [a total of 42 tests]). We also tested 
for interactions of each glucose measure with BMI, 
age, height, and mean arterial pressure in model 
II (105 tests). P values less than 0.001 were con-
sidered to indicate statistical significance for 
squared terms for glucose, age, BMI, and mean 
arterial pressure and interaction terms for all out-
comes, except neonatal hypoglycemia and shoul-
der dystocia or birth injury, for which P values less 
than 0.05 were considered to indicate statistical 
significance, owing to the smaller numbers of 
babies with these outcomes.
All analyses were conducted in SAS version 9.1 
or Stata 10.0. All reported P values are two-sided 
and were not adjusted for multiple testing.
R esult s
Participants
Among 53,295 eligible women (from 15 centers in 
nine countries; see the Appendix), 28,562 (53.6%) 
agreed to participate in this blinded study, between 
July 2000 and April 2006. Among the women who 
agreed to participate and those who refused to par-
ticipate, the mean age and years of education were 
29.0 and 12.9 years and 28.5 and 12.5 years, re-
spectively. A total of 25,505 women completed an 
oral glucose-tolerance test: 746 (2.9%) were exclud-
ed because their data were unblinded, 1412 (5.5%) 
were excluded primarily because they had under-
gone glucose testing or delivery outside the con-
text of the HAPO study, and 31 (0.1%) were ex-
cluded owing to missing key data or an implausible 
gestational age (>44 weeks); data from the remain-
ing 23,316 were available for analyses. Of these 
23,316 patients, 48.3% were self-reported to be 
white, 11.6% to be black, 8.5% to be Hispanic, 
29.0% to be “Asian or Oriental,” and 2.6% to be 
of other races or ethnic groups.
Characteristics of the mothers and newborns 
and pregnancy outcomes are summarized in Ta-
ble 1. The mean age of participants was 29.2 years, 
and the mean fasting, 1-hour, and 2-hour plasma 
glucose levels were 80.9 mg per deciliter (4.5 mmol 
per liter), 134.1 mg per deciliter (7.4 mmol per li-
ter), and 111.0 mg per deciliter (6.2 mmol per li-
ter), respectively. Correlations among these three 
glucose measures were as follows: 0.38 for the 
fasting plasma glucose level and the 1-hour plas-
ma glucose level, 0.30 for the fasting plasma glu-
cose level and the 2-hour plasma glucose level, 
and 0.68 for the 1-hour plasma glucose level and 
the 2-hour plasma glucose level (P<0.001 for all 
three comparisons). There were 2 maternal deaths 
(1 due to pulmonary embolism, the other due to 
respiratory failure secondary to pneumonia), 14 
cases of eclampsia, 321 cases of major malforma-
tion of the newborn, and 130 perinatal deaths (89 
fetal and 41 neonatal or infant) (incidence, 5.6 per 
1000) among the 23,316 deliveries.
Glycemia and Pregnancy Outcomes
Categorical Analyses
The frequency of each primary outcome across the 
seven glucose categories is shown in Figure 1. With 
increasing maternal glucose levels, the frequency 
of each primary outcome increased, although less 
so for clinical neonatal hypoglycemia than for the 
other outcomes. For example, for the fasting plas-
ma glucose level, frequencies in the lowest and 
highest categories, respectively, were 5.3% and 
26.3% for birth weight above the 90th percentile, 
13.3% and 27.9% for primary cesarean section, 
2.1% and 4.6% for clinical neonatal hypoglycemia, 
and 3.7% and 32.4% for C-peptide level above the 
90th percentile.
Table 2 shows the associations of maternal 
glucose as a categorical variable with each primary 
outcome, including odds ratios and 95% confi-
dence intervals for each category, as compared 
with the lowest category, with adjustment for con-
founders. There were strong associations with 
birth weight above the 90th percentile that in-
creased across the increasing glycemia categories. 
Differences in mean birth weight between the low-
est and highest categories of the fasting, 1-hour, 
and 2-hour plasma glucose levels were 242 to 
305 g when birth weight was modeled as a con-
tinuous variable, with adjustment for multiple 
confounders (data not shown). The odds ratio for 
primary cesarean section increased across catego-
ries of maternal glycemia and was 1.86 in the 
highest category of 1-hour plasma glucose; the 
odds ratio in the highest category of 2-hour plasma 
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glucose did not differ significantly from 1.00. The 
adjusted odds ratios for clinical neonatal hypogly-
cemia were substantially attenuated, and none of 
the odds ratios for the highest glucose categories 
were significantly different from 1.00. After ad-
justment for confounders, there was a strong as-
sociation between cord-blood serum C-peptide 
level above the 90th percentile and maternal glyce-
mia, with the association increasing with increas-
ing glycemia category; the odds ratio was 7.65 
(95% confidence interval [CI], 5.17 to 11.32) for the 
highest category of the fasting plasma glucose.
Continuous Analyses
Results for analyses of glucose level as a continu-
ous variable, with model II adjustment for both 
primary and secondary outcomes, are shown in 
Table 3. Among the primary outcomes, odds ra-
tios for an increase in the glucose level by 1 SD 
were highest for birth weight greater than the 90th 
percentile (range, 1.38 to 1.46) and cord-blood 
serum C-peptide level above the 90th percentile 
(range, 1.37 to 1.55). For primary cesarean sec-
tion and clinical neonatal hypoglycemia, the as-
sociations were weaker and the associations of 
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Figure 1. Frequency of Primary Outcomes across the Glucose Categories.
Glucose categories are defined as follows: fasting plasma glucose level — category 1, less than 75 mg per deciliter 
(4.2 mmol per liter); category 2, 75 to 79 mg per deciliter (4.2 to 4.4 mmol per liter); category 3, 80 to 84 mg per 
deciliter (4.5 to 4.7 mmol per liter); category 4, 85 to 89 mg per deciliter (4.8 to 4.9 mmol per liter); category 5, 90 to 
94 mg per deciliter (5.0 to 5.2 mmol per liter); category 6, 95 to 99 mg per deciliter (5.3 to 5.5 mmol per liter); and 
category 7, 100 mg per deciliter (5.6 mmol per liter) or more; 1-hour plasma glucose level — category 1, 105 mg per 
deciliter (5.8 mmol per liter) or less; category 2, 106 to 132 mg per deciliter (5.9 to 7.3 mmol per liter); category 3, 
133 to 155 mg per deciliter (7.4 to 8.6 mmol per liter); category 4, 156 to 171 mg per deciliter (8.7 to 9.5 mmol per 
liter); category 5, 172 to 193 mg per deciliter (9.6 to 10.7 mmol per liter); category 6, 194 to 211 mg per deciliter 
(10.8 to 11.7 mmol per liter); and category 7, 212 mg per deciliter (11.8 mmol per liter) or more; and 2-hr plasma 
glucose level — category 1, 90 mg per deciliter (5.0 mmol per liter) or less; category 2, 91 to 108 mg per deciliter 
(5.1 to 6.0 mmol per liter); category 3, 109 to 125 mg per deciliter (6.1 to 6.9 mmol per liter); category 4, 126 to 139 mg 
per deciliter (7.0 to 7.7 mmol per liter); category 5, 140 to 157 mg per deciliter (7.8 to 8.7 mmol per liter); category 6, 
158 to 177 mg per deciliter (8.8 to 9.8 mmol per liter); and category 7, 178 mg per deciliter (9.9 mmol per liter) or more.
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clinical neonatal hypoglycemia with the fasting 
plasma glucose level and the 2-hour plasma glu-
cose level were not significant.
Twelve of the 15 analyses of secondary out-
comes showed significant positive associations 
with maternal glycemia, after adjustment for con-
founders (Table 3). The strongest associations were 
found for preeclampsia, for which the odds ratio 
for each 1-SD increase in each glucose measure 
ranged from 1.21 to 1.28; corresponding odds ra-
tios for shoulder dystocia or birth injury were ap-
proximately 1.20. Premature delivery, intensive 
neonatal care, and hyperbilirubinemia were sig-
nificantly related to the 1-hour and 2-hour plasma 
glucose levels but not to the fasting plasma glu-
cose level.
The only significant quadratic (nonlinear) as-
sociation found in these analyses was for the fast-
ing plasma glucose level with clinical neonatal 
hypoglycemia (P = 0.01). Among the 147 tests for 
interactions, 7 were significant: the fasting plas-
ma glucose level with field center, in relation to 
primary cesarean delivery, in both models I and II 
(P<0.001); age with the fasting, 1-hour, and 2-hour 
plasma glucose levels, with regard to clinical neo-
natal hypoglycemia (P = 0.05, P = 0.03, and P = 0.001, 
respectively); BMI and 1-hour plasma glucose level, 
for clinical neonatal hypoglycemia (P<0.001); and 
mean arterial pressure with fasting plasma glu-
cose level, for premature delivery (P<0.001).
We also examined associations of glucose mea-
sures with birth weight below the 10th percentile 
for gestational age, using the same methods to 
estimate the 10th percentiles as were used to es-
Table 2. Adjusted Odds Ratios for Associations between Maternal Glucose as a Categorical Variable and Primary Outcomes.*
Glucose  
Category† Plasma Glucose Level
Fasting At 1 Hr At 2 Hr
total no.  
(no. with outcome)
odds ratio  
(95% CI)
total no.  
(no. with outcome)
odds ratio  
(95% CI)
total no.  
(no. with outcome)
odds ratio 
(95% CI)
Birth weight >90th percentile
1 4035 (213) 1.00 4177 (268) 1.00 4264 (297) 1.00
2 7501 (572) 1.37 (1.16–1.62) 7524 (584) 1.21 (1.04–1.41) 7422 (587) 1.11 (0.96–1.30)
3 6168 (622) 1.72 (1.46–2.03) 6003 (593) 1.65 (1.41–1.93) 5865 (580) 1.51 (1.30–1.75)
4 2741 (323) 1.95 (1.62–2.35) 2768 (352) 2.27 (1.91–2.71) 3024 (396) 2.15 (1.82–2.54)
5 1883 (310) 2.73 (2.25–3.31) 1858 (264) 2.66 (2.19–3.21) 1720 (210) 2.10 (1.73–2.56)
6 672 (124) 3.00 (2.34–3.86) 645 (111) 3.50 (2.72–4.50) 690 (101) 2.68 (2.08–3.45)
7 217 (57) 5.01 (3.54–7.09) 242 (49) 4.49 (3.16–6.39) 232 (50) 4.46 (3.15–6.33)
Primary cesarean section‡
1 3721 (495) 1.00 3826 (458) 1.00 3903 (535) 1.00
2 6806 (1151) 1.19 (1.06–1.34) 6792 (1113) 1.21 (1.07–1.36) 6664 (1032) 0.97 (0.86–1.09)
3 5483 (1014) 1.21 (1.07–1.37) 5311 (1032) 1.26 (1.11–1.42) 5201 (1017) 1.11 (0.99–1.26)
4 2378 (506) 1.33 (1.15–1.54) 2425 (522) 1.31 (1.13–1.52) 2650 (583) 1.15 (1.00–1.32)
5 1601 (380) 1.44 (1.23–1.69) 1623 (407) 1.48 (1.26–1.74) 1506 (350) 1.17 (0.99–1.37)
6 560 (134) 1.39 (1.11–1.75) 547 (132) 1.30 (1.04–1.64) 615 (162) 1.32 (1.08–1.63)
7 183 (51) 1.60 (1.12–2.27) 208 (67) 1.86 (1.35–2.57) 193 (52) 1.28 (0.91–1.81)
Clinical neonatal hypoglycemia
1 4043 (83) 1.00 4183 (72) 1.00 4266 (78) 1.00
2 7503 (144) 0.91 (0.69–1.21) 7523 (153) 1.12 (0.84–1.49) 7421 (134) 0.87 (0.66–1.17)
3 6164 (122) 0.92 (0.68–1.23) 6003 (131) 1.24 (0.92–1.68) 5868 (117) 0.96 (0.71–1.30)
4 2744 (59) 1.00 (0.70–1.43) 2772 (54) 1.11 (0.77–1.62) 3027 (80) 1.23 (0.88–1.71)
5 1884 (48) 1.19 (0.81–1.75) 1860 (45) 1.48 (0.99–2.22) 1720 (44) 1.13 (0.76–1.68)
6 672 (14) 1.01 (0.55–1.84) 643 (20) 2.17 (1.28–3.69) 693 (21) 1.36 (0.81–2.28)
7 217 (10) 1.98 (0.97–4.05) 243 (5) 1.29 (0.51–3.31) 232 (6) 1.12 (0.47–2.67)
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timate the 90th percentiles (Table 1). In the con-
tinuous-variable models, odds ratios for each 1-SD 
increase in glucose measures ranged from 0.77 to 
0.80, with no evidence of nonlinear associations 
(data not shown) and little difference from the 
results from unadjusted models.
Although the HAPO study did not have the 
statistical power to permit examination of perina-
tal death as a primary outcome, with only 130 
deaths, unadjusted analyses showed no increase in 
the risk of perinatal death with increasing glu-
cose levels. Unadjusted odds ratios for perinatal 
death for each 1-SD increase in the fasting, 1-hour, 
and 2-hour plasma glucose levels, respectively, 
were 0.91 (95% CI, 0.76 to 1.08), 0.93 (95% CI, 0.78 
to 1.11), and 0.99 (95% CI, 0.83 to 1.18), with no 
evidence of nonlinear associations.
Discussion
In 1952, Jorgen Pedersen22 postulated that ma-
ternal hyperglycemia led to fetal hyperglycemia, 
which evoked an exaggerated fetal response to in-
sulin. Since then, the Pedersen hypothesis has 
formed the basis for understanding the pathophys-
iological consequences of diabetes during preg-
nancy. The objective of the HAPO study was to 
clarify risks of adverse outcomes associated with 
degrees of maternal glucose intolerance less se-
vere than overt diabetes mellitus. The data pre-
sented here show associations between increasing 
levels of fasting, 1-hour, and 2-hour plasma glucose 
obtained on oral glucose-tolerance testing and 
birth weight above the 90th percentile and cord-
blood serum C-peptide level above the 90th per-
centile, with weaker associations between glucose 
levels and primary cesarean delivery and clinical 
neonatal hypoglycemia. We also found positive as-
sociations between increasing plasma glucose lev-
els and each of the five secondary outcomes ex-
amined: premature delivery, shoulder dystocia or 
birth injury, intensive neonatal care, hyperbiliru-
binemia, and preeclampsia.
Associations between maternal glycemia and 
Table 2. (Continued.)
Glucose  
Category† Plasma Glucose Level
Fasting 1 Hr 2 Hr
total no.  
(no. with outcome)
odds ratio  
(95% CI)
total no.  
(no. with outcome)
odds ratio  
(95% CI)
total no.  
(no. with outcome)
odds ratio 
(95% CI)
Cord-blood serum C peptide >90th percentile
1 3546 (131) 1.00 3593 (176) 1.00 3599 (193) 1.00
2 6453 (378) 1.41 (1.15–1.74) 6372 (366) 1.07 (0.88–1.29) 6353 (401) 1.06 (0.88–1.27)
3 5255 (429) 1.75 (1.42–2.15) 5132 (458) 1.62 (1.34–1.95) 5039 (440) 1.44 (1.20–1.73)
4 2308 (266) 2.36 (1.88–2.97) 2424 (274) 1.95 (1.58–2.41) 2609 (286) 1.72 (1.40–2.11)
5 1592 (181) 3.62 (2.87–4.58) 1607 (251) 2.76 (2.21–3.43) 1495 (202) 2.21 (1.77–2.76)
6 561 (131) 4.46 (3.36–5.93) 549 (95) 2.91 (2.18–3.89) 596 (109) 2.86 (2.18–3.77)
7 170 (55) 7.65 (5.17–11.32) 208 (51) 4.65 (3.19–6.79) 194 (40) 3.48 (2.33–5.21)
* Associations were adjusted for the following variables: field center, age, body-mass index, height, smoking status, alcohol use, presence or 
absence of family history of diabetes, gestational age at oral glucose-tolerance test, infant’s sex, presence or absence of hospitalization be-
fore delivery, mean arterial pressure (in all models), parity (0, 1, or ≥2; not included in the model for primary cesarean delivery), cord-blood 
plasma glucose level (included in the model for cord-blood serum C-peptide level >90th percentile only). Additional details are shown in 
Tables B, C, D, and E in the Supplementary Appendix. 
† Glucose categories are defined as follows: fasting plasma glucose level — category 1, less than 75 mg per deciliter (4.2 mmol per liter); cat-
egory 2, 75 to 79 mg per deciliter (4.2 to 4.4 mmol per liter); category 3, 80 to 84 mg per deciliter (4.5 to 4.7 mmol per liter); category 4, 85 
to 89 mg per deciliter (4.8 to 4.9 mmol per liter); category 5, 90 to 94 mg per deciliter (5.0 to 5.2 mmol per liter); category 6, 95 to 99 mg 
per deciliter (5.3 to 5.5 mmol per liter); and category 7, 100 mg per deciliter (5.6 mmol per liter) or more; 1-hour plasma glucose level — 
category 1, 105 mg per deciliter (5.8 mmol per liter) or less; category 2, 106 to 132 mg per deciliter (5.9 to 7.3 mmol per liter); category 3, 
133 to 155 mg per deciliter (7.4 to 8.6 mmol per liter); category 4, 156 to 171 mg per deciliter (8.7 to 9.5 mmol per liter); category 5, 172 to 
193 mg per deciliter (9.6 to 10.7 mmol per liter); category 6, 194 to 211 mg per deciliter (10.8 to 11.7 mmol per liter); and category 7, 212 
mg per deciliter (11.8 mmol per liter) or more; and 2-hr plasma glucose level — category 1, 90 mg per deciliter (5.0 mmol per liter) or less; 
category 2, 91 to 108 mg per deciliter (5.1 to 6.0 mmol per liter); category 3, 109 to 125 mg per deciliter (6.1 to 6.9 mmol per liter); category 
4, 126 to 139 mg per deciliter (7.0 to 7.7 mmol per liter); category 5, 140 to 157 mg per deciliter (7.8 to 8.7 mmol per liter); category 6, 158 
to 177 mg per deciliter (8.8 to 9.8 mmol per liter); and category 7, 178 mg per deciliter (9.9 mmol per liter) or more.
‡ Data for women who had had a previous cesarean section were excluded.
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adverse outcomes generally remained significant 
after adjustment for multiple potential confound-
ers — 10 of 12 associations for primary outcomes 
and 12 of 15 for secondary outcomes — and were 
generally consistent across centers, except the as-
sociation for the fasting plasma glucose level and 
primary cesarean delivery. Furthermore, findings 
with respect to cord-blood serum C-peptide levels, 
and hence fetal insulin levels, support Pedersen’s 
proposed mechanism to explain the propensity 
for excessive growth in fetuses of mothers with 
hyperglycemia. When associations between ma-
ternal glucose level and birth weight were esti-
mated with the use of birth weight as a continu-
ous variable, the difference in mean birth weight 
between the lowest and highest glucose categories 
was in the range of 240 to 300 g, even after full 
adjustment for potential confounders.
Two primary outcomes — birth weight above 
the 90th percentile and cord-blood serum C-pep-
tide level above the 90th percentile — though 
strongly associated with maternal glycemia, could 
be viewed as physiological consequences of ma-
ternal glycemia rather than as true disorders or 
problems. However, the other two primary out-
comes (primary cesarean delivery and clinical 
neonatal hypoglycemia) and the five secondary 
outcomes reported (premature delivery, shoulder 
dystocia or birth injury, intensive neonatal care, 
hyperbilirubinemia, and preeclampsia) also showed 
continuous linear associations with the 1-hour 
plasma glucose level (seven analyses), the 2-hour 
plasma glucose level (six analyses), and the fast-
ing plasma glucose level (three analyses). These are 
well-recognized complications of pregnancies in 
mothers with preexisting or gestational diabetes, 
as currently defined.
Questions have been raised regarding the 
benefits of treating “mild” gestational diabetes 
mellitus.13,23,24 However, one recently published 
randomized clinical trial, the Australian Carbo-
hydrate Intolerance Study in Pregnant Women 
(ACHOIS), found reduced perinatal morbidity and 
mortality when standard contemporary treatment 
of gestational diabetes mellitus was compared 
with no intervention25; another study on treatment 
of “mild” gestational diabetes mellitus is ongo-
ing.26 Taken together, the current results and re-
sults of the ACHOIS trial25 indicate that mater-
nal hyperglycemia less severe than that used to 
define overt diabetes is related to clinically impor-
tant perinatal disorders or problems and that their 
Table 3. Adjusted Odds Ratios for Associations between Maternal Glycemia as a Continuous Variable and Primary  
and Secondary Perinatal Outcomes.*
Outcome Plasma Glucose Level
Fasting At 1 Hr At 2 Hr
odds ratio (95% CI)
Primary outcome
Birth weight >90th percentile 1.38 (1.32–1.44) 1.46 (1.39–1.53) 1.38 (1.32–1.44)
Primary cesarean section† 1.11 (1.06–1.15) 1.10 (1.06–1.15) 1.08 (1.03–1.12)
Clinical neonatal hypoglycemia 1.08 (0.98–1.19)‡ 1.13 (1.03–1.26) 1.10 (1.00–1.12)
Cord-blood serum C peptide >90th percentile 1.55 (1.47–1.64) 1.46 (1.38–1.54) 1.37 (1.30–1.44)
Secondary outcome
Premature delivery (before 37 wk) 1.05 (0.99–1.11) 1.18 (1.12–1.25) 1.16 (1.10–1.23)
Shoulder dystocia or birth injury 1.18 (1.04–1.33) 1.23 (1.09–1.38) 1.22 (1.09–1.37)
Intensive neonatal care 0.99 (0.94–1.05) 1.07 (1.02–1.13) 1.09 (1.03–1.14)
Hyperbilirubinemia 1.00 (0.95–1.05) 1.11 (1.05–1.17) 1.08 (1.02–1.13)
Preeclampsia 1.21 (1.13–1.29) 1.28 (1.20–1.37) 1.28 (1.20–1.37)
* Odds ratios were for an increase in the glucose level of 1 SD (6.9 mg per deciliter [0.4 mmol per liter] for the fasting plas-
ma glucose level, 30.9 mg per deciliter [1.7 mmol per liter] for the 1-hr plasma glucose level, and 23.5 mg per deciliter 
[1.3 mmol per liter] for the 2-hr plasma glucose level). The model for preeclampsia did not include adjustment for hos-
pitalization or mean arterial pressure, and presence or absence of family history of hypertension or prenatal urinary tract 
infection was included in the model for preeclampsia only. See Table 2 for other details about adjustments in each model.
† Data for women who had had a previous cesarean section were excluded.
‡ The P value for the quadratic (nonlinear) association was 0.013.
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effects can be reduced by means of treatment, al-
though a threshold for the need for treatment is 
not established.
The individual measures from the oral glucose-
tolerance tests were not highly correlated, and no 
single measure was clearly superior in predicting 
the primary outcomes. When adjusted for poten-
tial confounders, relative increases in each glucose 
measure were similarly predictive of birth weight 
above the 90th percentile. When the glucose mea-
sures were analyzed as continuous variables, each 
was a significant predictor of primary cesarean 
delivery, with 1-SD increases in glucose level be-
ing associated with an increase of 8 to 11% in the 
odds of delivery by cesarean section. Clinical neo-
natal hypoglycemia was infrequent (overall inci-
dence, 2.1%), and when adjusted for confounders, 
only the 1-hour plasma glucose level remained a 
significant predictor of this outcome. All three 
measures of plasma glucose were highly predictive 
of cord-blood serum C-peptide values, with the 
fasting plasma glucose level being the strongest 
predictor.
Our study had some limitations. The nutritional 
status and gestational weight gain of the partici-
pants could affect fetal growth and other perinatal 
outcomes; we do not have data on these variables. 
Some confounders, such as previous gestational 
diabetes mellitus, maternal BMI, or previous mac-
rosomia, may have influenced clinical decisions 
such as the choice of route of delivery. Because of 
the observational design of our study, we cannot 
conclude that maternal glycemia is causally related 
to the adverse outcomes observed; however, such a 
relationship is plausible. Although the rate of par-
ticipation in this blinded study was 54%, we be-
lieve this is unlikely to materially affect our es-
timates of associations. Differences in age and 
education level were small between those who 
agreed to participate and those who did not.
The broad inclusion criteria, the large number 
and the geographic distribution of centers in-
volved, and the similarity across centers in the as-
sociations we found between maternal glycemia 
and outcomes provide support that our results can 
be generalized to develop outcome-based criteria 
for classifying glucose metabolism in pregnancy 
that can be applied worldwide. Lack of clear 
thresholds for risk and the fact that the four pri-
mary outcomes are not necessarily of equal clini-
cal importance make direct translation of our re-
sults into clinical practice challenging. However, 
our findings of significant associations between 
adverse outcomes and higher levels of maternal 
glucose within what is currently considered a non-
diabetic range indicate the need to reconsider cur-
rent criteria for diagnosing and treating hyper-
glycemia during pregnancy.
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K. Matheson, L. Mayes, K. McLean, H. Owen; European–Caribbean Field Centers — Queen Elizabeth Hospital–School of Clinical Medicine and 
Research, University of the West Indies, Barbados: C. Cave, G. Fenty, E. Gibson, A. Hennis, G. McIntyre, Y.E. Rotchell, C. Spooner, H.A.R. 
Thomas; Royal Jubilee Maternity Hospital, Belfast, Northern Ireland: J. Gluck, D.R. Hadden, H. Halliday, J. Irwin, O. Kearney, J. McAnee, D.R. 
McCance, M. Mousavi, A.I. Traub; St. Mary’s Hospital–Manchester University, Manchester, United Kingdom: J.K. Cruickshank, N. Derbyshire, J. 
Dry, A.C. Holt, F. Khan, C. Lambert, M. Maresh, F. Prichard, C. Townson; University Hospital–University Medical Center Utrecht, Utrecht, the 
Netherlands: T.W. van Haeften, A.M.R. van de Hengel, G.H.A. Visser, A. Zwart; Middle Eastern–Asian Field Centers — Rajavithi Hospital, 
Bangkok, Thailand: U. Chaovarindr, U. Chotigeat, C. Deerochanawong, I. Panyasiri, P. Sanguanpong; Soroka Medical Center–Ben-Gurion 
University, Beersheba, Israel: D. Amichay, A. Golan, K. Marks, M. Mazor, J. Ronen, A. Wiznitzer; Helen Schneider Hospital for Women, Rabin 
Medical Center–Sackler Faculty of Medicine, Tel-Aviv University, Petah-Tiqva, Israel: R. Chen, D. Harel, N. Hoter, N. Melamed, J. Pardo, M. Wit-
shner, Y. Yogev; Australasian Field Centers — Mater Misericordiae Mothers’ Hospital–University of Queensland, Brisbane, Australia: F. Bowling, D. 
Cowley, P. Devenish-Meares, H.G. Liley, A. McArdle, H.D. McIntyre, B. Morrison, A. Peacock, A. Tremellen, D. Tudehope; Prince of Wales 
Hospital–Chinese University of Hong Kong, Hong Kong: K.Y. Chan, N.Y. Chan, L.W. Ip, S.L. Kong, Y.L. Lee, C.Y. Li, K.F. Ng, P.C. Ng, M.S. 
Rogers, K.W. Wong; John Hunter Hospital, Newcastle, Australia: M. Edgar, W. Giles, A. Gill, R. Glover, J. Lowe, F. Mackenzie, K. Siech, J. 
Verma, A. Wright; KK Women’s and Children’s Hospital, Singapore City, Singapore: Y.H. Cao, J.J. Chee, A. Koh, E. Tan, V.J. Rajadurai, H.Y. Wee, 
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